Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension.

Stage 1 hypertension: SBP 140-159 or DBP 90-99 Stage 2 hypertension: SBP ≥160 or DBP ≥100 For patients age 50 or older, elevated SBP is a stronger cardiovascular risk factor than elevated DBP.

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary ...

Pulmonary hypertension (PH) can be challenging for ... about the medications available to treat PAH, including the drug classes and specific drugs that make up these categories.

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

functional class, and reduced risk of clinical worsening events for people with WHO group 1 pulmonary hypertension. These "dramatic" benefits in ZENITH provide a mandate for use, noted study ...

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary ...